Jeannot, V. Et Al. 2016. Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. ONCOTARGETS AND THERAPY , vol.9 , 6843-6855.

Jeannot, V., Busser, B., Vanwonterghem, L., Michallet, S., Ferroudj, S., ÇOKOL, M., ... Coll, J.(2016). Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. ONCOTARGETS AND THERAPY , vol.9, 6843-6855.

Jeannot, Victor Et Al. "Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma," ONCOTARGETS AND THERAPY , vol.9, 6843-6855, 2016

Jeannot, Victor Et Al. "Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma." ONCOTARGETS AND THERAPY , vol.9, pp.6843-6855, 2016

Jeannot, V. Et Al. (2016) . "Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma." ONCOTARGETS AND THERAPY , vol.9, pp.6843-6855.

@article{article, author={Victor Jeannot Et Al. }, title={Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma}, journal={ONCOTARGETS AND THERAPY}, year=2016, pages={6843-6855} }